Indian generic drugmaker Cipla posted a bigger-than-expected 32% rise in third-quarter profit on Monday, driven by strong performance in its North American business.
Consolidated net profit climbed to Rs 1056 crore ($127.1 million) in the quarter ended Dec. 31, beating analysts’ average estimate of Rs 1043 crore, as per LSEG data.
MORE TO COME…
